Biobeat Technologies secured a $50 million in a new Series B funding round from strategic investors, including Ally Bridge Group (lead investor), OrbiMed Advisors, and Elevage Medical Technologies.
According to the Biobeat, the fresh proceeds of funds will further boost its commercialization efforts in the United States. The latest round reflects strong and accelerating demand for its ambulatory blood pressure monitoring devices.
As part of the investment, Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed, and Evan Melrose of Elevage will join the Biobeat Board of Directors.
Arik Ben Ishay is the CEO and co-founder of Biobeat, a developer of wearable AI-powered remote patient monitoring solutions. Biobeat has corporate offices in Tel Aviv, Israel, and Boca Raton, Florida. The startup is developing a blood pressure monitoring system for hypertensive patients that captures critical nighttime BP measurements seamlessly and accurately, and sends the data to a companion app.
According to our funding tracker, Digital Health companies secured more than $20 billion VC funding in 2025. More recently, Tebra, a leading provider of practice management software solutions, secured an oversubscribed $250 million funding round that includes new equity and debt financing.